K Pharma (4896) · RiskMitigated
Share Price Declines from Sales by Venture Capital Investors
First written in FY2023. 2 of 3 entries say "Mitigated", first in FY2024. Latest entry: FY2025.
3entries
3years
0from disclosures
How it moved
Same theme, other companies
Deterioration in Supply and Demand from Share Sales by Venture Capital Firms and OthersA theme 62 companies write about · 62 as a headwind · 0 as a tailwind
The whole theme swung hardest in 2019: 2 of 13 companies on the "Worse" side.
20 other companies' latest entry also says "Mitigated".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 62 companies compared. The sentences above are computed from all 62.Full recordFilings, disclosures and news, newest first
- FY2025MitigatedAnnual report
「As of the end of the fiscal year, venture capital firms and investment limited partnerships established by venture capital firms held 18.4% of our total shares outstanding.」
The holding ratio of venture capital firms and others fell from 27.4% to 18.4%. The company continues to disclose the risk that share sales could weaken supply and demand and lower the share price. - FY2024MitigatedAnnual report
「As of the end of the fiscal year, venture capital firms and investment limited partnerships established by venture capital firms held 27.4% of our total shares outstanding.」
The holding ratio of venture capital firms and others fell from 29.0% to 27.4%. The company continues to describe the risk that sales could weaken supply and demand and lower the share price. - FY2023First statedAnnual report
「As of the end of the fiscal year, venture capital firms and investment limited partnerships established by venture capital firms held 29.0% of our total shares outstanding.」
The company states that venture capital firms and others held 29.0%, and describes the possibility that post-listing sales could weaken supply and demand and lower the share price.